Cariprazine Capsules bulk supplier for pharma manufacturers

Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg Suppliers & Bulk Manufacturers

Available Forms: Oral Capsules

Available Strengths: 1.5 mg, 3 mg, 4.5 mg, 6 mg

Reference Brands: Vraylar®(US); Reagila®(EU)

Cariprazine 1.5 mg, 3 mg, 4.5 mg and 6 mg hard capsules, a dopamine D3/D2 partial agonist antipsychotic for schizophrenia and bipolar disorder. For psychiatric hospital pharmacies, distributors and importers.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Cariprazine Capsules? List it or send an offer →

Product Description:

Cariprazine is a third-generation antipsychotic. It is a partial agonist at dopamine D3 and D2 receptors, with a notably high affinity for D3, and at serotonin 5-HT1A receptors, and it blocks 5-HT2B and 5-HT2A receptors. Partial agonism damps excess dopamine signalling without shutting it off. Cariprazine and its active metabolites have very long half-lives, so levels take weeks to settle and persist after stopping. This page covers hard capsules of 1.5 mg, 3 mg, 4.5 mg and 6 mg for once-daily dosing and stepwise titration.

Cariprazine is approved for schizophrenia in the US and the EU. The US label also covers manic or mixed episodes of bipolar I disorder, bipolar I depression and add-on treatment of major depressive disorder. Treatment starts at 1.5 mg once daily and is increased in steps. Because of the long half-life, side effects can emerge weeks after a dose change. Akathisia and other extrapyramidal symptoms are most common, and weight, glucose and lipids are monitored. Strong CYP3A4 inhibitors require dose reduction, and inducers are avoided.

Sourcing notes. Cariprazine is prescription-only. Patent and data-protection status differs by market, so check whether generic registration is possible in your country before ordering. Specify the strengths needed, as starting and maintenance strengths sell in different volumes, plus capsules per pack and blister type. Request the CTD or ACTD dossier, stability data for your climatic zone including Zone IVb, a certificate of analysis for every batch, the GMP certificate and a CoPP. Ask for the impurity profile and confirmation of a nitrosamine risk assessment, which regulators increasingly expect.

Cariprazine Capsules — third party manufacturing & bulk supply

Cariprazine Capsules 1.5 mg, 3 mg, 4.5 mg, 6 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Cariprazine Capsules is supplied as Oral Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Cariprazine Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Cariprazine Capsules →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Cariprazine is used to treat psychiatric conditions such as schizophrenia and bipolar disorder. It helps manage symptoms like hallucinations, delusions, mood swings, and agitation, improving overall mental stability and daily functioning.

Cariprazine is a synthetic pharmaceutical compound that acts as a dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist. It is manufactured under controlled pharmaceutical processes to ensure consistent therapeutic effects and safety.

Cariprazine is marketed under the brand name Vraylar in the United States and other regions.

Cariprazine (Vraylar) is manufactured and marketed by Recordati Pharmaceuticals, with distribution in multiple countries through authorized partners.

The generic name is Cariprazine.

The most recognized brand name is Vraylar.

Cariprazine is manufactured in regulated pharmaceutical facilities that comply with international quality and safety standards, including sites in the United States, Europe, and other approved markets.